AC Immune is headquartered in Lausanne, Switzerland.
AC Immune disclosed revenue of 27M USD for 2024 and 15M USD for 2023.
AC Immune has 133 employees.
AC Immune is a life science company.
AC Immune was founded in 2003.
EPFL Innovation Park, Building B,
Lausanne,
1015
Switzerland,
+41 21 345 91 21
www.acimmune.com
AC Immune is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune was founded in 2003 and is based in Lausanne, Switzerland.
| Year | ≤ '20 | '21 | '22 | '23 | '24 | '25 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.2/yr) | # | - | 1 | - | - | - | - | 1 |
| vol | $59M | $59M | ||||||
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 1 | ||||||||
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
